BCL9 and neoplasm: Consistently, the CXCL9 expression by cDC1 and CXCR3 expression by CD8+ T cells were upregulated in tumors from hsBCL9z96-treated CT26 tumor-bearing mice, as well as from MC38 tumor-bearing Bcl9/Bcl9l deficiency mice (Fig. 7g–i).